Poniard Pharmaceuticals, Inc.
Records under this name other than patents Poniard Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Poniard Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,505,719 | Synthesis and use of kinase inhibitors Formerly held Lapsed on the fee record Ended Nov 29, 2020 · USPTO record | Lapsed on the fee record | Ended Nov 29, 2020 | USPTO record |
| US 9,375,402 | Oral formulations of kinase inhibitors Formerly held Lapsed on the fee record Ended Jun 28, 2020 · USPTO record | Lapsed on the fee record | Ended Jun 28, 2020 | USPTO record |
| US 8,178,564 | Use of Picoplatin to Treat Colorectal Cancer Formerly held Lapsed on the fee record Ended May 15, 2020 · Low confidence | Lapsed on the fee record | Ended May 15, 2020 | Low confidence |
| US 8,173,686 | Use of Picoplatin to Treat Colorectal Cancer Formerly held Lapsed on the fee record Ended May 8, 2020 · Low confidence | Lapsed on the fee record | Ended May 8, 2020 | Low confidence |
| US 8,168,661 | Use of Picoplatin to Treat Colorectal Cancer Formerly held Lapsed on the fee record Ended May 1, 2020 · Low confidence | Lapsed on the fee record | Ended May 1, 2020 | Low confidence |
| US 8,168,662 | Use of Picoplatin to Treat Colorectal Cancer Formerly held Lapsed on the fee record Ended May 1, 2020 · Low confidence | Lapsed on the fee record | Ended May 1, 2020 | Low confidence |
| US 6,117,551 | Carbon fiber prepreg, and a production process thereof Term ended Term ended Aug 11, 2018 · USPTO record | Term ended | Term ended Aug 11, 2018 | USPTO record |
| US 6,251,920 | Prevention and treatment of cardiovascular pathologies Term ended Term ended May 21, 2018 · USPTO record | Term ended | Term ended May 21, 2018 | USPTO record |
| US 6,197,789 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues Term ended Term ended Dec 5, 2017 · USPTO record | Term ended | Term ended Dec 5, 2017 | USPTO record |
| US 6,166,090 | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells Term ended Term ended Nov 6, 2017 · USPTO record | Term ended | Term ended Nov 6, 2017 | USPTO record |